456160.KQ G2GBIO Inc.

Healthcare Biotechnology KOSDAQ
35,600 KRW
Close of Oct 30, 2026
22,400 124,000
Market cap
KRW 592B
P/E
-
P/B
4.27x
ROE
-16.2%
Dividend yield
-
Fundamental score
1.1/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 456160.KQ undervalued?

Graham number

The Graham number of G2GBIO Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

G2GBIO Inc. fundamental analysis

5 of 21 checks passed

ROE 0/2

Low return on equity (-16.2%), below 10%.

ROA 1/1

Return on assets (-9.6%) is above the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (85.8%) is above the industry median (4.8%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (0.5%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Cash Runway 0/2

Cash covers 1.0 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (4.3x) is above the industry median (2.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

G2GBIO Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About G2GBIO Inc.

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company's pipeline products include GB-5001, GB-5001A, and GB-5112 for the treatment of Alzheimer's disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 f…

Full company profile